BLFS: financial statements from SEC — TradeAlmanac

BLFS

BioLife Solutions, Inc.: financial statements

Company reports as filed with the U.S. Securities and Exchange Commission.

AnnualQuarterly

Income statement

Metric	Mar 31, 2026	Sep 30, 2025	Jun 30, 2025	Mar 31, 2025	Sep 30, 2024	Jun 30, 2024
Revenue	28m	28m	25m	24m	21m	20m
Cost of revenue	10m	—	—	7m	—	—
Gross profit	17m	—	—	15m	—	—
Research and development	3m	3m	3m	2m	2m	2m
Selling, general and administrative	12m	12m	11m	12m	9m	9m
Operating expenses	17m	28m	42m	25m	22m	21m
Operating income	27,000	−89,000	−17m	−1m	−418,000	−1m
Pre-tax income	1m	703,000	−16m	−434,000	−551,000	−6m
Income tax	62,000	82,000	126,000	14,000	−80,000	1,000
Net income	1m	621,000	−16m	−448,000	−2m	−21m
Earnings per share	0.02	0.01	−0.33	−0.01	−0.04	−0.45
Earnings per share, diluted	0.02	0.01	−0.33	−0.01	−0.04	−0.45
Weighted average shares	48m	48m	48m	47m	46m	46m
Weighted average shares, diluted	49m	49m	48m	47m	46m	46m

Balance sheet

Metric	Mar 31, 2026	Dec 31, 2025	Sep 30, 2025	Jun 30, 2025	Mar 31, 2025	Dec 31, 2024	Sep 30, 2024	Jun 30, 2024
Cash and equivalents	23m	33m	29m	32m	67m	92m	24m	22m
Receivables	13m	8m	11m

Cash flow

Metric	Mar 31, 2026	Mar 31, 2025
Operating cash flow	−491,000	2m
Depreciation and amortisation	374,000	682,000
Share-based compensation	5m	4m
Capital expenditure	167,000	175,000
Investing cash flow	−2m	−27m
Financing cash flow	−8m

Amounts in USD unless stated otherwise. Sources: Nasdaq Trader, Yahoo Finance, U.S. Securities and Exchange Commission (EDGAR)